Back to Journals » ClinicoEconomics and Outcomes Research » Volume 10

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Total article views   HTML views PDF downloads Totals
12,713 Dovepress* 9,989+ 1,707 11,696
PubMed Central* 2,724 514 3,238
Totals 12,713 2,221 14,934
*Since 23 April 2018
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed Central and Google Scholar